SecSonar.com

Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Atara Biotherapeutics, Inc. (ATRA) is a Biotechnology company based in US with a market capitalization of $94.9M. Revenue declined 6.3% year-over-year and free cash flow was negative at -$50.9M. This page tracks ATRA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 153 employees · IPO Oct 16, 2014

Valuation

Valuation & price

$9.58 · as of May 17, 2026 · -47.0% vs 52w high

3.7

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$18.00$11.09$4.18Jul 25Dec 25Jul 26Jul 7, 25$8.58Jul 9, 25$9.23Jul 11, 25$9.23Jul 15, 25$9.27Jul 17, 25$9.71Jul 21, 25$11.50Jul 23, 25$12.26Jul 25, 25$11.58Jul 29, 25$11.73Jul 31, 25$11.52Aug 4, 25$11.32Aug 6, 25$11.39Aug 11, 25$10.32Aug 13, 25$12.13Aug 15, 25$12.29Aug 19, 25$11.48Aug 21, 25$11.49Aug 25, 25$12.24Aug 27, 25$12.35Aug 29, 25$12.05Sep 3, 25$12.63Sep 5, 25$12.91Sep 9, 25$11.95Sep 11, 25$12.16Sep 16, 25$11.51Sep 18, 25$12.07Sep 22, 25$12.30Sep 24, 25$14.26Sep 26, 25$13.74Sep 30, 25$14.33Oct 2, 25$14.48Oct 6, 25$13.98Oct 8, 25$15.85Oct 10, 25$14.33Oct 14, 25$14.61Oct 16, 25$15.25Oct 21, 25$15.79Oct 23, 25$14.12Oct 27, 25$15.59Oct 29, 25$14.06Oct 31, 25$14.85Nov 4, 25$12.29Nov 6, 25$11.82Nov 10, 25$12.30Nov 12, 25$12.47Nov 14, 25$13.76Nov 18, 25$13.46Nov 20, 25$13.22Nov 25, 25$14.57Nov 28, 25$15.10Dec 2, 25$12.22Dec 4, 25$14.20Dec 8, 25$15.08Dec 10, 25$16.83Dec 12, 25$18.00Dec 16, 25$17.58Dec 18, 25$17.23Dec 22, 25$17.86Dec 24, 25$17.59Dec 29, 25$17.99Jan 2, 26$17.77Jan 6, 26$14.57Jan 8, 26$17.44Jan 12, 26$5.88Jan 14, 26$4.47Jan 16, 26$4.54Jan 21, 26$4.60Jan 23, 26$5.22Jan 27, 26$5.56Jan 29, 26$5.51Feb 2, 26$5.04Feb 4, 26$4.86Feb 9, 26$4.98Feb 11, 26$4.59Feb 13, 26$4.45Feb 18, 26$4.43Feb 20, 26$4.18Feb 24, 26$4.21Feb 26, 26$5.26Mar 2, 26$4.91Mar 4, 26$5.39Mar 6, 26$5.17Mar 10, 26$6.29Mar 12, 26$6.90Mar 17, 26$5.23Mar 19, 26$5.12Mar 23, 26$4.85Mar 25, 26$4.96Mar 27, 26$4.59Mar 31, 26$4.73Apr 2, 26$4.99Apr 7, 26$4.71Apr 9, 26$4.83Apr 13, 26$4.89Apr 15, 26$5.24Apr 17, 26$5.27Apr 22, 26$5.18Apr 24, 26$5.01Apr 28, 26$4.73Apr 30, 26$4.77May 4, 26$4.88May 6, 26$5.15May 8, 26$8.34May 12, 26$9.81May 14, 26$9.59May 18, 26$9.15May 20, 26$9.45May 22, 26$9.80May 28, 26$11.26Jun 1, 26$10.28Jun 3, 26$9.63Jun 5, 26$9.92Jun 9, 26$9.77Jun 11, 26$10.46Jun 15, 26$9.96Jun 17, 26$9.67Jun 22, 26$10.61Jun 24, 26$10.55Jun 26, 26$10.51Jul 2, 26$11.65
$4.1852-week range$18.09
Loading valuation history…

Fundamentals

Key fundamentals

$94.9M

Market cap

-6.3%

Revenue growth (YoY)

82.4%

Gross margin

-$50.9M

Free cash flow (USD)

$44.3M

Net debt

67.5%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$20.3MFY 2022$63.6MFY 2023$8.6MFY 2024$128.9MFY 2025$120.8M
$0$120.8M

Free cash flow by year

2016 → 2025

FY 2016$-63.0MFY 2017$-107.7MFY 2018$-215.7MFY 2019$-241.4MFY 2020$-185.3MFY 2021$-231.1MFY 2022$-274.6MFY 2023$-194.2MFY 2024$-69.0MFY 2025$-50.9M
-$63M-$50.9M

Gross margin by year

2021 → 2025

FY 2021-1286.4%FY 2022100.0%FY 2023-3.6%FY 202483.7%FY 202582.4%
-1286.4%82.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCFO AppointmentJun 26, 2026Filing
  • 8-K eventDirector AppointmentJun 12, 2026Filing
  • Insider sellInsider Sell $22KGrant-Huerta Yanina · Chief Accounting Officer · $22KMay 20, 2026Filing
  • Insider sellInsider Sell $48KNguyen AnhCo · Director, President and CEO · $47.8KMay 20, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • Insider buyInsider Buy $4.7MEcoR1 Capital, LLC · 10% Owner · $4.7MMay 11, 2026Filing
  • Insider sellInsider Sell $3.2MPanacea Innovation Ltd · 10% Owner · $3.2MMay 11, 2026Filing
  • 8-K eventRegulatory UpdateMay 7, 2026Filing
  • 8-K eventDelisting NoticeMay 1, 2026Filing

Questions

Frequently asked questions

What is Atara Biotherapeutics, Inc.'s market cap?

Atara Biotherapeutics, Inc. (ATRA) has a market capitalization of $94.9M.

What is ATRA's P/E ratio?

ATRA trades at a price-to-earnings ratio of 3.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

Are insiders buying ATRA stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 3 sells at Atara Biotherapeutics, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

CAMP

CAMP4 Therapeutics Corporation

$93.6M

FBIO

Fortress Biotech, Inc.

$93.3M

ANIX

Anixa Biosciences, Inc.

$92.2M

NRXS

NeurAxis, Inc.

$89.9M

ICCC

ImmuCell Corporation

$89.6M

DTIL

Precision BioSciences, Inc.

$89.5M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.